Dallas 2015 TFQO: Vinay Nadkarni #375 EVREV 1: Vinay Nadkarni #375 EVREV 1: Dave Kloeck #126 Taskforce: Paeds Paed 424: Vasopressors in Paediatric cardiac.

Slides:



Advertisements
Similar presentations
Dallas 2015 TFQO: Tony Scott #138 EVREV 1: Tony Scott #138 EVREV 2: Anthony Seto # Taskforce: ACS Supplemental Oxygen in ACS 887.
Advertisements

Dallas 2015 TFQO: Allan de Caen COI#38 EVREV 1: Melissa Parker COI#259 EVREV 1: Takanari Ikeyama COI#235 Taskforce: Pediatrics Peds 820 : The use of fluids.
Dallas 2015 TFQO: Myra Wyckoff #COI EVREV 1: Myra Wyckoff #COI EVREV 2: Lindsay Mildenhall #107 Taskforce: NRP NRP: 605 Two thumb verses two finger.
Dallas 2015 TFQO: Marya Strand, MD, MS; COI#222 EVREV 1: Marya Strand, MD, MS; COI#222 EVREV 1: Takahiro Sugiura, MD; COI#224 Taskforce: NLS Umbilical.
Dallas : CPAP and IPPV In spontaneously breathing preterm infants with respiratory distress requiring respiratory support in the delivery room,
Chicago 2014 TFQO: Kee-Chong Ng (#COI = 113) EVREV 1: Gene Ong (#COI = 118) EVREV 2: Jos Bruinenberg (#COI = 19) Taskforce: Pediatric Taskforce The Long.
Dallas 2015 TFQO: S. Velaphi COI #242 EVREVs: N. Singhal COI#213 H. Ersdal COI#76 Taskforce: Neonatal Maintaining Infant Temperature During Delivery Room.
Dallas 2015 TFQO: EVREVs: de Almeida, Maria Fernanda COI# Trevisanuto, Daniele COI# Taskforce: Neonatal Warming Adjunts #599 Among preterm neonates who.
Chicago 2014 Peter Morley, Eddy Lang E3, GRADE expert Incorporating lower levels of evidence.
Critically Evaluating the Evidence: Tools for Appraisal Elizabeth A. Crabtree, MPH, PhD (c) Director of Evidence-Based Practice, Quality Management Assistant.
Summarising findings about the likely impacts of options Judgements about the quality of evidence Preparing summary of findings tables Plain language summaries.
Dallas 2015 TFQO: David Stanton COI 328 EVREVs: Volker Wenzel COI 253& Emmanuelle Bourdon COI 333 Taskforce: BLS Passive ventilation techniques.
Dallas 2015 TFQO: Karen Woolfrey COI #261 EVREV 1: Karen Woolfrey COI 261 EVREV 2: Daniel Pichel COI # 513 Taskforce: ACS ACS 335: Pre-hospital ADP- Receptor.
Dallas 2015 TFQO: Jerry Nolan #310 EVREV 1: Jerry Nolan COI #301 EVREV 2: Charles Deakin COI #221 Taskforce: ALS ALS 714 : Advanced airway placement (SGA.
Peds-818: Pediatric Early Warning Scores
Dallas 2015 TFQO: Vinay Nadkarni MD COI#249 EVREV 1: Graeme Maclaren MBBS COI#98 EVREV 2: Ravi Thiagarajan MBBS, MPH COI#149 Taskforce: PALS Peds 819 :
Dallas 2015 TFQO: Karen Woolfrey COI #261 EVREV 1: Karen Woolfrey COI #261 EVREV 2: Daniel Pichel COI #513 Taskforce: ACS ACS 873: Pre-hospital STEMI Activation.
Dallas 2015 TFQO: Jeffry Pearlman COI# 187 EVREV 1: Enrique Udaeta COI# 239 EVREV 1: Edgardo Ezslyd COI# 277 Taskforce: NRP Laryngeal Mask Airway (NRP.
Felix I. Zemel, MPH DrPH Student Tufts University School of Medicine.
Dallas 2015 TFQO: EVREVs: Aaron Donoghue / Jonathan Duff Taskforce: EIT Teaching Compression-Only CPR.
6th June 2004 By Norah A A Al Khathlan M.D. JOURNAL CLUB A Comparison of High-Dose and Standard-dose Epinephrine in Children with Cardiac Arrest NEJM 350;17April.
Dallas 2015 TFQO: Masanori Tamura #147 EVREV 1: Masanori Tamura #147 EVREV 2: Susan Niermeyer #252 Delayed Cord Clamping in Preterm Infants Including those.
Using GRADEpro to create Evidence Profiles and Summary of Findings Tables Wednesday 19 January to 1330 (PT) Nancy Santesso McMaster University.
Therapeutic Hypothermia in Out of Hospital Cardiac Arrest towards
NRP: 862: Use of Feedback CPR Devices for Neonatal Cardiac Arrest NRP: 863: Use of Feedback CPR Devices to detect ROSC for Neonatal Cardiac Arrest TFQO:
Study design P.Olliaro Nov04. Study designs: observational vs. experimental studies What happened?  Case-control study What’s happening?  Cross-sectional.
Chicago 2014 TFQO: Peter Meaney #COI 149 EVREV 1: Richard Aickin #COI 153 EVREV 1: Peter Meaney #COI 149 Taskforce: Pediatrics Resuscitation fluids (Peds)
Dallas 2015 TFQO: Marilyn Escobedo COI#78 EVREV 1: Marilyn Escobedo COI#78 EVREV 2: Henry Lee COI#135 Taskforce: NRP Babies born to mothers who are hypothermic.
Dallas 2015 TFQO: Robert Greif EVREVs: Jan Breckwoldt, Henrik Fischer Taskforce: Education Implementation and Training (EIT) AED training methods.
Dallas 2015 TFQO: Enrique Udaeta COI# 239 EVREV 1: Enrique Udaeta COI# 239 EVREV 1: Edgardo Ezslyd COI# 277 Taskforce: NRP Laryngeal Mask Airway (NRP 618)
Dallas 2015 TFQO: EVREVs: Guinsburg, Ruth COI# McGowan, Jane COI# Taskforce: Neonatal Apgar Zero #896 In infants ≥36 weeks GA with an Apgar score.
Dallas 2015 TFQO: Name EVREV 1: Jonathan Wyllie COI #282 EVREV 1: Jeff Perlman COI #262 Taskforce: Newborn Temperature Maintenance in the Delivery room.
Chicago 2014 TFQO: Nikolaos Nikolaou COI#253 EVREV 1: Nikolaos Nikolaou COI#253 EVREV 2: Farzin BeyguiCOI#202 Taskforce: ACS STEMI transfer PCI vs. FL.
Chicago 2014 TFQO: Darren Walters COI #317 EVREV 1: Darren Walters COI #317 EVREV 2: Chris Ghaemmaghami COI #60 Taskforce: Acute Coronary Syndrome In STEMI.
Dallas 2015 TFQO: Anne-Marie Guerguerian # 97 EVREV1: Anne-Marie Guerguerian # 97 EVEREV2: Ericka Fink # 83 Taskforce: PEDS Peds 407 : ECMO for pediatric.
Dallas 2015 TFQO: Darren Walters EVREVs: EVREV 1: Darren Walters COI #422 EVREV 2: Chris Ghaemmaghami COI #89 Taskforce: Acute Coronary Syndrome Fibrinolytic.
First Aid 801: Stroke Recognition
Dallas 2015 TFQO: Name and #COI EVREV 1: Name and #COI Taskforce: Name Insert Short PICO title (including unique PICO ID#) Total of 4 (maximum) using standard.
Dallas 2015 TFQO: David Boyle COI #26 EVREV 1: David Boyle #COI#26 EVREV 1: Jane McGowan #370 Taskforce: Neonatal Ventilation Strategies in the DR (NRP.
Dallas 2015 TFQO: Name and #COI EVREV 1: Name and #COI Taskforce: Name Insert Short PICO title (including unique PICO ID#) Total of 6 (maximum) using standard.
WHO GUIDANCE FOR THE DEVELOPMENT OF EVIDENCE-BASED VACCINE RELATED RECOMMENDATIONS August 2011.
Dallas 2015 TFQO: Michael Sayre COI #400 EVREV 1: Mohamud Daya COI #327 EVREV 2: Jan-Thorsten Gräsner COI #230 Taskforce: BLS BLS 363: CPR Prior to Defibrillation.
Chicago 2014 TFQO: Charles Deakin #329 EVREV 1: Asger Granfeldt COI #63 EVREV 2: Bo Lofgren COI #363 Taskforce: ALS ALS 571 : Ventilation strategy post-ROSC.
Dallas 2015 TFQO: Allan de Caen COI #38 EVREV 1: Tia Raymond COI #153; EVREV 2: Jonathan Egan COI #44 Taskforce: Peds The role of invasive vascular monitoring.
UT Southwestern Medical Center at Dallas
Dallas 2015 TFQO: Kee-Chong Ng (#COI = 170) EVREV 1: Gene Ong (#COI = 118) EVREV 2: Jos Bruinenberg (#COI = 19) Taskforce: Pediatric Taskforce The Long.
This material was developed by Oregon Health & Science University, funded by the Department of Health and Human Services, Office of the National Coordinator.
Chicago 2014 Pediatric RRT/MET Teams #397 TFQO: Dianne Atkins COI #7 EVREV 1: Dianne Atkins EVREV 2: Kee Chong Ng COI #113 Taskforce: Peds.
TFQO: Jasmeet Soar #COI 272 EVREV 1: Jasmeet Soar #COI 272 EVREV 2: Michael Donnino #COI 222 Taskforce: ALS ALS 448 OXYGEN DOSE AFTER ROSC IN ADULTS 3.
Dallas 2015 TFQO: Maaret Castrén #320 EVREV 1: Christian Vaillancourt #416 EVREV 2: Michael Sayre #400 Taskforce: BLS BLS 359: Dispatcher Instructions.
Dallas 2015 TFQO: Jan Jensen COI #115 EVREVs: Jan Jensen COI #115 Richard N. Bradley COI #151 Taskforce: First Aid 769: Hemostatic Dressings.
Dallas 2015 TFQO: Monica Kleinman COI #353 EVREV 1: Janice Tijssen COI#232 EVREV 2: Javier Urbano COI#240 Taskforce: Peds Peds 815: Pediatric goal-directed.
Dallas 2015 TFQO: Judith Finn EVREVs: Judith Finn #227 / Dion Stub #COI Taskforce: EIT Cardiac Arrest Centres.
Dallas 2015 TFQO: Michael W. Donnino COI# EVREVs: Katherine M. Berg COI# Lars W. Andersen COI# Taskforce: ALS Ultrasound During CPR.
Dallas 2015 TFQO: Jan Jensen COI #115 EVREV: Michael Reilly COI #193 Taskforce: First Aid First Aid 768: Use of Tourniquet.
Dallas 2015 TFQO: Koen Monsieurs 372 EVREV 1: Koen Monsieurs 372 EVREV 2: Ahamed Idris 349 Taskforce: BLS BLS366 Chest Compression Depth (adults)
Dallas 2015 TFQO: Jerry Nolan #310 EVREV 1: Jerry Nolan COI #301 EVREV 2: Jan-Thorsten Graesner COI #150 Taskforce: ALS ALS 783 : Advanced versus basic.
Dallas 2015 TFQO: Robert Greif EVREVs: Dana Edelson, COI #334 Robert Greif, COI #344 Taskforce: EIT EIT 645: Debriefing of resuscitation performance.
Dallas 2015 TFQO: Hiroshi Nonogi #254 EVREVs: Hiroshi Nonogi #254 Tony Scott #138 Taskforce: ACS Fibrinolytic and immediate PCI for STEMI 882.
LINC Trial LUCAS in cardiac arrest trial. What is LINC? A multicenter, randomized, controlled trial designed to evaluate the efficacy and safety of: LUCAS.
Dallas 2015 TFQO: S. Velaphi EVREV 1: N. Singhal COI #213 EVREV 2: S. Velaphi COI #242 EVREV 3: H. Ersdal – COI # 76 Taskforce: NLS Prognosis: In newborn.
Dallas 2015 TFQO: Karen Woolfrey #COI 261 EVREV 1: Karen Woolfrey # COI 261 EVREV 2: Daniel Pichel #COI 513 Taskforce: ACS ACS 872: Pre-hospital Diversion.
Dallas 2015 TFQO: Name EVREVs: Names and #COI Taskforce: Name Insert Short PICO title Total of 12 (no studies) to 20 slides (maximum) using standard format.
Dallas 2015 TFQO: Jonathan Witt (COI #418) EVREVs: Steve Lin (COI #137), Thomas Pellis (COI #186) and Katie Dainty (COI #) Taskforce: ALS ALS 428 : Antiarrhythmic.
Chicago 2014 TFQO: Clifton Callaway # EVREV 1: Janice Zimmerman # EVREV 2: Jonathan Sullivan COI # Taskforce: ALS ALS 790 : Induced Hypothermia.
GRADE Grading of Recommendations Assessment, Development and Evaluation British Association of Dermatologists April 2014.
Abstract Cardiopulmonary Resuscitation with Rescue Breathing Is Superior to Hands-Only Cardiopulmonary Resuscitation for Children and Infants: Results.
Dallas 2015 TFQO: Jasmeet Soar #COI 409 EVREV 1: Jasmeet Soar #COI 409 EVREV 2: Anthony Lagina #COI 357 Taskforce: ALS ALS 889 OXYGEN DOSE DURING CPR IN.
Dallas 2015 TFQO: Michael Donnino #222 EVREV 1: Joshua Reynolds COI #265 EVREV 2: Katherine Berg COI #10 Taskforce: ALS ALS 790 : Induced Hypothermia.
What is LINC? A multicenter, randomized, controlled trial
Presentation transcript:

Dallas 2015 TFQO: Vinay Nadkarni #375 EVREV 1: Vinay Nadkarni #375 EVREV 1: Dave Kloeck #126 Taskforce: Paeds Paed 424: Vasopressors in Paediatric cardiac arrest

Dallas 2015 COI Disclosure (specific to this systematic review) Vinay Nadkarni COI#375 Commercial/industry Nil Potential intellectual conflicts Nil Dave Kloeck COI#126 Commercial/industry Nil Potential intellectual conflicts Nil

Dallas CoSTR In adult and pediatric patients with cardiac arrest (prehospital [OHCA] or in hospital [IHCA])(P),does the use of vasopressin or vasopressin+epinephrine (I)compared with standard treatment recommendations(C), improve outcome (e.g.,ROSC, survival to hospital discharge, or survival with favorable neurologic outcome) (O)? New question specific to Paeds – PICO edited to read - Infants and children in cardiac arrest (P), does use of NO vasopressor (epinephrine, vasopressin, combination of vasopressors) (I), compared with ANY use of vasopressors (C), change survival to 180 days with good neurological outcome, survival to hospital discharge, ROSC (O)?

Dallas 2015 C2015 PICO Population: Infants and children in cardiac arrest Intervention: Does the use of NO vasopressor (epinephrine, vasopressin, combination of vasopressors) Comparison: Compared with ANY use of vasopressors Outcomes: Survival to 180 days with good neurological outcome (9 – Critical) Survival to hospital discharge (6 – Important) ROSC (5 – Important)

Dallas 2015 Inclusion/Exclusion & Articles Found Inclusions: (all studies) Infants and paediatrics Animals – paediatric and infant Number of articles initially identified = 1360 narrowed down to 10 articles Number finally included in Evidence Profile tables RCTs = 0 non-RCTs = 2 Excluded = 8 Later in review process – 1 adult RCT identified to answer the PICO question (ALS #788)– included into SoF but downgraded heavily for indirectness

Dallas 2015 #ALS 788

Dallas Proposed Treatment Recommendations None We suggest no change to current practise in using vasopressors for paediatric cardiac arrest Strength of evidence is very low with very serious downgrades in quality assessment for inconsistency, indirectness, imprecision and risk of bias

Dallas 2015 Risk of Bias in studies Non-RCT bias asssesment StudyYearDesign Total Patients Population Industry Funding Eligibility Criteria Exposure/Outcome Confounding Follow up Kevin Enright 2012Non-RCT9Paediatric-OHCANoLowHigh Low Ronald Diekmann 1995Non-RCT65Paediatric-OHCANoLowHigh Low RCT bias assessment StudyYearDesign Total Patients Population Industry Funding Allocation: Generation Allocation: Concealment Blinding: Participants Blinding: Assessors Outcome: Complete Outcome: Selective Other Bias Ian Jacobs2011RCT534Adults - OHCANoLow High – 67 pts (11%) post randomization excl Low High – 989 consecutive cases, of which 601 randomized (unexplained) & trial terminated early due to lack of enthusiasm by providers

Dallas 2015 Evidence profile table

Dallas 2015 Evidence profile table

Dallas 2015 Proposed Consensus on Science statements For the critical outcome of “survival with good neurological outcome” we have identified very low quality evidence (downgraded for indirectness, imprecision, inconsistency and high risk of bias) from two pediatric out of hospital case series observational studies including 74 patients suggesting uncertain benefit. (Enright, 2012, 336 & Diekmann, 1995, 901)(Pooled unadjusted OR % CI 1.49 – 47.13). For the important outcome of “survival to hospital discharge” we have identified very low quality evidence (downgraded for indirectness, imprecision, inconsistency and high risk of bias) from two pediatric out of hospital case series observational studies including 74 patients suggesting uncertain benefit. (Enright, 2012, 336 & Diekmann, 1995, 901) (Pooled unadjusted OR % CI 1.2 – 25.8).

Dallas 2015 Proposed Consensus on Science statements For the important outcome of “ROSC” we have identified very low quality evidence (downgraded for indirectness, imprecision, inconsistency and high risk of bias) from two pediatric out of hospital case series observational studies including 74 patients suggesting uncertain benefit. (Enright, 2012, 336 & Diekmann, 1995, 901) (Pooled unadjusted OR % CI 1.5 to 29.7). Note: (See Adult PICO question #788) For all critical and important outcomes, we reviewed and considered a single underpowered ADULT out-of-hospital cardiac arrest RCT that provided very low quality evidence (downgraded for extreme indirectness, imprecision and risk of bias) comparing Standard Dose Epinephrine to placebo (Jacobs, 2011, 1138). For the critical outcome “good neurological outcome” and important outcome of “survival to discharge”, there was uncertain benefit or harm of standard dose epinephrine compared to placebo. For the important outcomes of “Survival to Hospital Admission” and “ROSC”, there was possible benefit of standard dose epinephrine compared to placebo.

Dallas 2015 Draft Treatment Recommendations For paediatrics in cardiac arrest we suggest no change in the current approach. Therefore no change in the current practice of using vasopressors for paediatric cardiac arrest. Strength of evidence is very low with very serious downgrades in quality assessment for inconsistency, indirectness, imprecision and risk of bias

Dallas 2015 Knowledge Gaps If adult studies suggest that vasopressor administration is associated with improved ROSC, but worse survival to hospital discharge and neurological outcome then prospective studies of placebo vs epinephrine/vasopressors for paediatric cardiac arrest would be indicated. Are there selected resuscitation circumstances (e.g. pulmonary hypertension, myocarditis, imminent ECPR rescue) where the administration of vasopressors is not indicated?

Dallas 2015 Next Steps Task force discussion – TR not appropriate and needs better wordsmithing  proposal below: There is insufficient evidence of benefit or harm from using no vasopressors compared to any vasopressors to treat infants and children in cardiac arrest. Until specific studies of this question, We suggest providers continue to use epinephrine for pediatric cardiac arrest as per their current council-specific practice